Brief: Merus Announces First Patient Dosed In LiGeR-HN2
24/07/2024 13:17
July 24 (Reuters) - Merus NV 2GH.F :
* MERUS ANNOUNCES FIRST PATIENT DOSED IN LIGER-HN2, A PHASE
3
TRIAL EVALUATING PETOSEMTAMAB IN 2/3L R/M HNSCC
Source text for Eikon: ID:nGNXbcLpyk
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab